Canntab Therapeutics Limited Stock Probability of Future Pink Sheet Price Finishing Under 0.0001
| CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab |
Canntab Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Canntab Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Canntab Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
Canntab Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Canntab Pink Sheet often depends not only on the future outlook of the current and potential Canntab Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Canntab Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.9 M |
Canntab Therapeutics Technical Analysis
Canntab Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Canntab Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Canntab Therapeutics Limited. In general, you should focus on analyzing Canntab Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Canntab Therapeutics Predictive Forecast Models
Canntab Therapeutics' time-series forecasting models is one of many Canntab Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Canntab Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Canntab Therapeutics
Checking the ongoing alerts about Canntab Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Canntab Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.